explore | Grilled Cheese

Poland's AOTMiT refuses reimbursement for oral edaravone imported for amyotrophic lateral sclerosis. https://www.mattheneus.com/editorial/aotmit-radicut-edaravone-oral-suspension-als-targeted-import-non-recommendation-2026-09-28 #HTA #RegulatoryAffairs #HealthEconomics

📢 Upcoming Webinar: GLP-1–Induced Weight Loss and the Female Obesity Penalty

📅 October 5, 2026
🕖 3:30 PM – 4:30 PM UTC + 0

Announcing the 2026 Anne Mills Health Economics Lecture #healtheconomics

Fully Funded PhD; Deadline: 19th Oct How implementation processes influence the cost-effectiveness of healthcare interventions #healtheconomics

How much could withdrawing heart-failure therapy after AF remission change five-year costs? #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/withdraw-af-heart-failure-therapy-withdrawal-cost-minimisation-2026-09-27

Four coverage cases reveal what behavioural interventions need for reimbursement across cost, engagement and scalability. https://www.mattheneus.com/editorial/behavioural-intervention-coverage-cost-engagement-scalability-2026-09-28 #HTA #HealthEconomics

Utility mapping can fail exactly where accuracy matters most for survivors in poor health. https://www.mattheneus.com/editorial/gynaecological-cancer-eq5d-mapping-low-utility-accuracy-2026-09-27 #HTA #HealthEconomics #EvidenceSynthesis

Health-state mapping can be least accurate where decisions are most sensitive: survivors in the poorest health. https://www.mattheneus.com/editorial/gynaecological-cancer-eq5d-mapping-low-utility-accuracy-2026-09-27 #HTA #HealthEconomics #EvidenceSynthesis

How much does a complication advantage drive value? Tubular lumbar decompression stayed cheaper even after that advantage disappeared. #HTA #HealthEconomics https://www.mattheneus.com/editorial/lumbar-decompression-cost-effectiveness-complication-threshold-model-2026-09-27

Zero eligible trials can still guide policy. Germany’s colorectal screening review maps a critical evidence gap. https://www.mattheneus.com/editorial/iqwig-colorectal-screening-age-interval-zero-trial-model-2026-04-15 #HTA #EvidenceSynthesis #HealthEconomics

Can bedtime dosing improve hypertension outcomes? A five-trial network meta-analysis offers an exploratory ranking. https://www.mattheneus.com/editorial/pubmed-antihypertensive-chronotherapy-star-network-ranking-2026-09-25 #HTA #NMA #EvidenceSynthesis #HealthEconomics

Sweden’s TLV estimates Kisunla at SEK 1.55m–4.54m per QALY, showing how durability assumptions drive value. https://www.mattheneus.com/editorial/tlv-kisunla-donanemab-cost-effectiveness-durability-scenarios-2026-09-22 #HTA #HealthEconomics #Pharma

Africa’s childhood vaccine evidence base contained just one budget-impact analysis, exposing a critical gap for decision-makers. https://www.mattheneus.com/editorial/africa-childhood-vaccine-economic-evidence-budget-impact-gap-2026-09-24 #HTA #HealthEconomics #EvidenceSynthesis

Tenecteplase may improve outcomes and lower costs versus alteplase after acute ischaemic stroke in Canada. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pubmed-tenecteplase-alteplase-act-trial-canada-cost-effectiveness-2026-09-24

Swedish survival projections rose when trial follow-up doubled, showing the sensitivity of HTA extrapolations. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-swedish-hta-oncology-survival-extrapolation-extended-follow-up-audit-2026-09-26

The University of Manchester (@manchester.ac.uk) is hiring:
Research Associate in Health Economics

Value-based price shifts with population eligibility: GBP 4,410 at list price, GBP 612 for the top tenth. https://www.mattheneus.com/editorial/cost-effectiveness-demand-curve-value-based-price-population-eligibility-2026-09-25 #HTA #HealthEconomics

A costed menu for global evidence synthesis infrastructure puts 40 solutions at US$278.3 million. https://www.mattheneus.com/editorial/evidence-synthesis-infrastructure-costed-menu-data-duplication-investment-2026-09-21 #HTA #EvidenceSynthesis #HealthEconomics